Abstract

Among new peptides responsible for the pathogenesis of metabolic disorders and carbohydrate metabolism, adipokines are of great importance. Adipokines are substances of hormonal character, secreted by adipose tissue. Apart from the well-known adipokines, adropin and preptin are relatively newly discovered, hence their function is not fully understood. They are peptides not secreted by adipose tissue but their role in the metabolic regulations seems to be significant. Preptin is a 34-amino acid peptide, a derivative of proinsulin growth factor II (pro-IGF-II), secreted by pancreatic β cells, considered to be a physiological enhancer of insulin secretion. Additionally, preptin has a stimulating effect on osteoblasts, inducing their proliferation, differentiation and survival. Adropin is a 76-amino acid peptide, encoded by the energy homeostasis associated gene (Enho), mainly in liver and brain, and its expression is dependent on a diet. Adropin is believed to play an important role in metabolic homeostasis, fatty acids metabolism control, insulin resistance prevention, dyslipidemia, and impaired glucose tolerance. The results of studies conducted so far show that the diseases resulting from metabolic syndrome, such as obesity, type 2 diabetes mellitus, polycystic ovary syndrome, non-alcoholic fatty liver disease, or cardiovascular disease are accompanied by significant changes in the concentration of these peptides. It is also important to note that preptin has an anabolic effect on bone tissue, which might be preventive in osteoporosis.

References

• 1. Altincik A., Sayin O.: Evaluation of the relationship between serumadropin levels and blood pressure in obese children. J. Pediatr.Endocrinol. Metab., 2015; 28: 1095-1100
  Google Scholar
• 2. Aslan M., Celik O., Karsavuran N., Celik N., Dogan D.G., Botan E.,Kafkasli A.: Maternal serum and cord blood preptin levels in gestationaldiabetes mellitus. J. Perinatol., 2011; 31: 350-355
  Google Scholar
• 3. Aydin S.: Three new players in energy regulation: preptin, adropinand irisin. Peptides, 2014; 56: 94-110
  Google Scholar
• 4. Aydin S., Kuloglu T., Aydin S., Kalayci M., Yilmaz M., Çakmak T.,Eren M.N.: Elevated adropin: a candidate diagnostic marker for myocardialinfarction in conjunction with troponin-I. Peptides, 2014;58: 91-97
  Google Scholar
• 5. Barber T.M., McCarthy M.I., Franks S., Wass J.A.: Metabolic syndromein polycystic ovary syndrome. Endokrynol. Pol., 2007; 58:34-41
  Google Scholar
• 6. Baykus Y., Gurates B., Aydin S., Celik H., Kavak B., Aksoy A., SahinI., Deniz R., Gungor S., Guzel S.P., Minareci Y.: Changes in serumobestatin, preptin and ghrelins in patients with gestational diabetes mellitus. Clin. Biochem., 2012; 45: 198-202
  Google Scholar
• 7. Bu Z., Kuok K., Meng J., Wang R., Xu B., Zhang H.: The relationshipbetween polycystic ovary syndrome, glucose tolerance status andserum preptin level. Reprod. Biol. Endocrinol., 2012; 10: 10
  Google Scholar
• 8. Buchanan C.M., Phillips A.R., Cooper G.J.: Preptin derived fromproinsulin-like growth factor II (proIGF-II) is secreted from pancreaticislet β-cells and enhances insulin secretion. Biochem. J., 2001;360: 431-439
  Google Scholar
• 9. Butler A.A., Tam C.S., Stanhope K.L., Wolfe B.M., Ali M.R., O’KeeffeM., St-Onge M.P., Ravussin E., Havel P.J.: Low circulating adropinconcentrations with obesity and aging correlate with risk factorsfor metabolic disease and increase after gastric bypass surgery inhumans. J. Clin. Endocrinol. Metab., 2012; 97: 3783-3791
  Google Scholar
• 10. Celik E., Yilmaz E., Celik O., Ulas M., Turkcuoglu I., Karaer A.,Simsek Y., Minareci Y., Aydin S.: Maternal and fetal adropin levelsin gestational diabetes mellitus. J. Perinat. Med., 2013; 41: 375-380
  Google Scholar
• 11. Celik O., Celik N., Hascalik S., Sahin I., Aydin S., Ozerol E.: Anappraisal of serum preptin levels in PCOS. Fertil. Steril., 2011; 95:314-316
  Google Scholar
• 12. Cheng K.C., Li Y.X., Asakawa A., Ushikai M., Kato I., Sato Y., ChengJ.T., Inui A.: Characterization of preptin-induced insulin secretionin pancreatic β-cells. J. Endocrinol., 2012; 215: 43-49
  Google Scholar
• 13. Cornish J., Callon K.E., Bava U., Watson M., Xu X., Lin J.M., ChanV.A., Grey A.B., Naot D., Buchanan C.M., Cooper G.J., Reid I.R.: Preptin,another peptide product of the pancreatic β-cell, is osteogenic in vitroand in vivo. Am. J. Physiol. Endocrinol. Metab., 2007; 292: E117-E122
  Google Scholar
• 14. Ehrmann D.A., Barnes R.B., Rosenfield R.L., Cavaghan M.K., ImperialJ.: Prevalence of impaired glucose tolerance and diabetes inwomen with polycystic ovary syndrome. Diabetes Care, 1999, 22:141-146
  Google Scholar
• 15. El-Eshmawy M., Abdel Aal I.: Relationships between preptin andosteocalcin in obese, overweight, and normal weight adults. Appl.Physiol. Nutr. Metab., 2015; 40: 218-222
  Google Scholar
• 16. Galluzzo A., Amato M.C., Giordano C.: Insulin resistance andpolycystic ovary syndrome. Nutr. Metab. Cardiovasc. Dis., 2008; 18:511-518
  Google Scholar
• 17. Gao S., McMillan R.P., Zhu Q., Lopaschuk G.D., Hulver M.W., ButlerA.A.: Therapeutic effects of adropin on glucose tolerance andsubstrate utilization in diet-induced obese mice with insulin resistance.Mol. Metab., 2015; 4: 310-324
  Google Scholar
• 18. Kamińska A., Kopczyńska E., Bieliński M., Borkowska A., Junik R.:Visfatin concentrations in obese patients in relation to the presenceof newly diagnosed glucose metabolism disorders. Endokrynol.Pol., 2015; 66: 108-113
  Google Scholar
• 19. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J.,Larson M.G., Kannel W.B., Vasan R.S.: Obesity and the risk of heartfailure. N. Engl. J. Med., 2002; 347: 305-313
  Google Scholar
• 20. Kocaoglu C., Buyukinan M., Erdem S.S., Ozel A.: Are obesity andmetabolic syndrome associated with plasma adropin levels in children?J. Pediatr. Endocrinol. Metab., 2015; 28: 1293-1297
  Google Scholar
• 21. Kowalczyk R., Yang S.H., Brimble M.A., Callon K.E., WatsonM., Park Y.E., Cornish J.: Synthesis of truncated analogues of preptin-(1–16),and investigation of their ability to stimulate osteoblastproliferation. Bioorg. Med. Chem., 2014; 22: 3565-3572
  Google Scholar
• 22. Krzyżanowska-Świniarska B., Zahorska-Markiewicz B., OstrowskaL., Bąk-Sosnowska M.: Zaburzenia odżywiania. Otyłość (prosta,pokarmowa). W: Endokrynologia Kliniczna, tom. 1, red.; A. Milewicz,2012: 345-364
  Google Scholar
• 23. Kumar K.G., Trevaskis J.L., Lam D.D., Sutton G.M., Koza R.A.,Chouljenko V.N., Kousoulas K.G., Rogers P.M., Kesterson R.A., Thearle M., Ferrante A.W. Jr., Mynatt R.L., Burris T.P., Dong J.Z., HalemH.A., Culler M.D., Heisler L.K., Stephens J.M., Butler A.A.: Identificationof adropin as a secreted factor linking dietary macronutrientintake with energy homeostasis and lipid metabolism. Cell Metab.,2008; 8: 468-481
  Google Scholar
• 24. Kumar K.G., Zhang J., Gao S., Rossi J., McGuinness O.P., HalemH.H., Culler M.D., Mynatt R.L., Butler A.A.: Adropin deficiency is associatedwith increased adiposity and insulin resistance. Obesity,2012; 20: 1394-1402
  Google Scholar
• 25. Li N., Zheng Y.B., Han J., Liang W., Wang J.Y., Zhou J.R., ShenY., Zhang J.: Lower circulating preptin levels in male patients withosteoporosis are correlated with bone mineral density and boneformation. BMC Musculoskelet. Disord., 2013; 14: 49
  Google Scholar
• 26. Lovren F., Pan Y., Quan A., Singh K.K., Shukla P.C., Gupta M.,Al-Omran M., Teoh H., Verma S.: Adropin is a novel regulator ofendothelial function. Circulation, 2010; 122 (Suppl. 11): S185-S192
  Google Scholar
• 27. Naot D., Cornish J.: Cytokines and hormones that contributeto the positive association between fat and bone. Front. Endocrinol.,2014; 5: 70
  Google Scholar
• 28. Olszanecka-Glinianowicz M., Kocełak P., Orlik B., Handzlik G.,Juszczyk Ł.: Nowe adipokiny – korzystne czy niekorzystne w aspekciepatogenezy insulinooporności? Endokrynol. Otył. Zab. Przem.Mat., 2009; 5: 236-244
  Google Scholar
• 29. Ozkan Y., Timurkan E.S., Aydin S., Sahin I., Timurkan M., Citil C.,Kalayci M., Yilmaz M., Aksoy A., Catak Z.: Acylated and desacylatedghrelin, preptin, leptin, and nesfatin-1 Peptide changes related tothe body mass index. Int. J. Endocrinol., 2013; 2013: 236085
  Google Scholar
• 30. Pacholczyk M., Ferenc T., Kowalski J.: Zespół metaboliczny. CzęśćI: Definicje i kryteria rozpoznawania zespołu metabolicznego. Epidemiologiaoraz związek z ryzykiem chorób sercowo-naczyniowychi cukrzycy typu 2. Postępy Hig. Med. Dośw., 2008; 62: 530-542
  Google Scholar
• 31. Pukajło K., Łaczmański Ł., Kolackov K., Kuliczkowska-Płaksej J.,Bolanowski M., Milewicz A., Daroszewski J.: Irisin plasma concentrationin PCOS and healthy subjects is related to body fat contentand android fat distribution. Gynecol. Endocrinol., 2015; 31: 907-911
  Google Scholar
• 32. Reid I.R.: Fat and bone. Arch. Biochem. Biophys., 2010; 503: 20-27
  Google Scholar
• 33. Sayın O., Tokgöz Y., Arslan N.: Investigation of adropin and leptinlevels in pediatric obesity-related nonalcoholic fatty liver disease.J. Pediatr. Endocrinol. Metab., 2014; 27: 479-484
  Google Scholar
• 34. Yang G., Li L., Chen W., Liu H., Boden G., Li K.: Circulating preptinlevels in normal, impaired glucose tolerance, and type 2 diabeticsubjects. Ann. Med., 2009; 41: 52-56
  Google Scholar
• 35. Yildirim B., Celik O., Aydin S.: Adropin: a key component andpotential gatekeeper of metabolic disturbances in polycystic ovariansyndrome. Clin. Exp. Obstet. Gynecol., 2014; 41: 310-312
  Google Scholar
• 36. Yu H.Y., Zhao P., Wu M.C., Liu J., Yin W.: Serum adropin levelsare decreased in patients with acute myocardial infarction. Regul.Pept., 2014; 190-191: 46-49
  Google Scholar
• 37. Zdrojewski T., Bandosz P., Szpakowski P., Konarski R., ManikowskiA., Wołkiewicz E., Jakubowski Z., Łysiak-Szydłowska W., BautembachS., Wyrzykowski B.: Rozpowszechnienie głównych czynnikówryzyka chorób układu sercowo-naczyniowego w Polsce: wynikibadania NATPOL PLUS. Kardiol. Pol., 2004; 61 (Suppl. 4): IV1-IV26
  Google Scholar
• 38. Zuo C., Huang Y., Bajis R., Sahih M., Li Y.P., Dai K., Zhang X.: Osteoblastogenesisregulation signals in bone remodeling. Osteoporos.Int., 2012; 23: 1653-1663
  Google Scholar

Full text